Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01916434
Other study ID # 2005
Secondary ID
Status Completed
Phase N/A
First received August 2, 2013
Last updated March 24, 2016
Start date March 2013
Est. completion date March 2016

Study information

Verified date March 2016
Source University of Aberdeen
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

Consumption of fish can help to prevent cardiovascular disease. The precise way in which fish is beneficial is not fully understood. This is important to find out as fish consists of a complex mixture of fatty acids and micronutrients such as vitamin D and selenium that could individually, or collectively, be responsible for the beneficial effects.

Fish farming in Scotland is playing an increasingly important role in the provision of fish for human consumption. But issues with sustainability of raw materials are requiring fish farming to reformulate fish diets, which may affect the levels of beneficial omega-3 fatty acids and other components in fish.

In this study we will be comparing the long-term health effects of eating two portions a week of Scottish salmon raised on a traditional fish diet versus eating two portions a week of Scottish salmon raised on a more sustainable fish diet. In addition, we will be looking at differences in health outcomes when eating two portions a week of either Scottish salmon, compared with eating no fish at all.


Description:

Aquaculture has the potential to take the pressure off wild fish stocks whilst meeting the dietary needs of the population for omega 3 fatty acids and other key nutrients such as vitamin D. The industry is working hard to improve sustainability - between 1995 and 2006 it has been estimated that the input to output ratios for salmon improved from 7.5 to 4.9 and trout from 6.0 to 3.4- but there is a need to do more. Reductions in fish stocks and catch quotas, in addition to sustainability considerations, mean that farmed fish may have to be raised on vegetable oils for example but this may reduce the omega 3 content and may affect the content of other nutrients. Fish are an important component of the diet and there is a need to understand the effect of pressures from sustainability on methods of production and the health giving properties of fish. We have now been commissioned by the Scottish Government's Rural and Environment Science and Analytical Services Division (RESAS) to do research on the health effects of Scottish farmed fish fed different feeding regimes in the Scottish population, and assess how differential effects in measured health outcomes could be related to fish composition.

Consumption of fish or omega-3- fatty acids from fish reduces coronary heart disease mortality, the leading cause of death in developed nations. The precise way in which fish provides benefit is not fully understood. This is important as fish and fish oils consist of a complex mixture of fatty acids and micronutrients that could individually, or collectively, be responsible for the beneficial effects. Aquaculture in Scotland is playing an increasingly important role in the provision of fish for human consumption, but issues with sustainability are requiring aquaculture to replace traditional fish oil and meal in formulated fish diets by oil from more sustainable sources, which may affect the levels of beneficial omega-3 fatty acids (EPA and DHA) and other components in fish. We will investigate the health effects of consuming two portions oily fish (Scottish farmed salmon) per week (current UK recommendation) using fish raised on different feeding regimes.

HYPOTHESIS

The health effects of consuming two portions oily fish (Scottish farmed salmon) per week (current UK recommendation) will be different for fish raised on different feeding regimes, primarily in terms of improving the omega-3 index.

OBJECTIVE

The main objective of this proposed study is to determine 1) whether the health benefits of consuming two portions of Scottish farmed salmon per week that have been fed a diet high in fish oil and fish meal significantly outweigh the health benefits of consuming two portions of Scottish farmed salmon per week that have been fed a diet with more sustainable levels of fish meal and fish oil, and 2) whether the difference in health benefits could justify the use of less sustainable dietary regimes for farmed fish.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date March 2016
Est. primary completion date March 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 35 Years to 75 Years
Eligibility Inclusion criteria: Healthy men and women aged 35-75 years BMI ranging from 18-35 kg/m2 Blood pressure below 160/90 mmHg; Total cholesterol < 8.00 mmol/L Total/HDL cholesterol < 6 mmol/L Fasting plasma glucose , 7 mmol/L Having a 10-20% risk for developing cardiovascular disease within the next 10 years based on the ASSIGN calculation (http://cvrisk.mvm.ed.ac.uk/index.htm) including the following factors: age, gender, number of cigarettes smoked per day, Scottish Index of Multiple Deprivation (SIMD)/postcode, systolic blood pressure, levels of total and HDL cholesterol and family history of cardiovascular disease, or having at least one additional risk factor such as being over 50 years old, BMI above 25 kg/m2, elevated triglyceride levels (> 1.7 mmol/L) or elevated glucose levels (> 5.6 mmol/L); platelet count > 1709/L haematocrit above 40 % for males and above 35 % for females haemoglobin above 130 g/L for males and above 115 g/L for females

Exclusion criteria Regularly taking aspirin or aspirin-containing drugs, or other anti-inflammatory drugs; Taking drugs or herbal medicines known to alter the haemostatic system in general; Taking any medicine known to affect lipid metabolism; Taking certain dietary supplements/multivitamin tablets; Diagnosis of diabetes, hypertension, renal, hepatic, haematological disease or coronary heart disease; Unsuitable veins for blood sampling; Inability to understand the participant information sheet; inability to speak, read and understand the English language.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Other:
High PUFA Salmon Fillets
High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
Sustainable PUFA salmon
'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
No salmon
The placebo group will continue to consume their habitual diet.

Locations

Country Name City State
United Kingdom Rowett Institute of Nutrition and Health, Human Nutrition Unit Aberdeen

Sponsors (1)

Lead Sponsor Collaborator
University of Aberdeen

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Bleeding time as measured by the platelet function analyzer (PFA-100) The PFA-100 simulates high shear platelet function in citrated blood within disposable test cartridges with membranes coated with either collagen/epinephrine (CEPI) or collagen/ADP (CADP). The presence of these platelet activators and the high shear rates under the standardised conditions result in platelet adhesion, activation and aggregation resulting in formation of a platelet plug within the aperture. Platelet function is thus measured as a function of the time it takes to occlude the aperture. At baseline and after 18 weeks salmon consumption No
Other Markers of coagulation and endothelial activation. Fibrinogen is a principle plasma glycoprotein involved in blood clotting. Plasma clottable fibrinogen levels will be measured by Clauss method on a semi-automated coagulometer using Fibrinogen assay thrombin reagent from Helena Biosciences, England. Von Willebrand factor (vWF) is another plasma glycoprotein involved in coagulation and an established marker of endothelial activation or damage. Plasma levels of vWF will be measured by an in-house ELISA using polyclonal antibodies and horseradish peroxidase-conjugated antibody from DAKO Ltd, Denmark. P-selectin is a cell adhesion molecule present in platelet granules and (to a lesser extent) in endothelial cells. sP-selectin levels in fasted blood plasma will be measured in duplicate by ELISA (Bender Med Systems) At baseline and after 18 weeks salmon consumption No
Other Markers of inflammation. CRP is an acute phase protein synthesised by the liver in response to inflammatory stimuli, especially the cytokine IL-6. hsCRP will be measured in duplicate by an ultra sensitive, double antibody ELISA. Soluble -ICAM is a marker of endothelial activation and inflammation, during which it promotes leucocyte adherence to the endothelium. Plasma soluble I-CAM levels will be measured in duplicate by ELISA (Bender Med Systems). Epoxyeicosatrieonic acids (EETs) are anti-inflammatory and cardioprotective compounds. Their availability and metabolism are regulated by the enzyme soluble epoxide hydrolase (sEH), which in turn is affected by EPA. EETs will be measured in platelets using LC-MS/MS. At baseline and after 18 weeks salmon consumption No
Other Markers of oxidative stress. F2-isoprostanes are currently considered as reference biomarkers for lipid peroxidation and will be measured by LC-MS/MS. At baseline and after 18 weeks salmon consumption No
Other Markers of micronutrient availability Selenium in incorporated into proteins within the body, many of which are antioxidants that protect the body against oxidative damage. Selenium is transported across the body within the protein, selenoprotein P (SEPP-1). Selenium status will be measured by assaying plasma selenium levels (by ICP-MS) and by quantification of plasma SEPP-1 levels (by an in-house ELISA). Iodine status will be measured by assaying urinary iodine levels (by ICP-MS) and vitamin D status will be assessed by measuring plasma 25-hydroxy vitamin D (using HPLC and LC/MS/MS). At baseline and after 18 weeks salmon consumption No
Other Markers of gut health Faecal samples will be collected for the isolation of faecal waters to measure NFkb activation, micronutrient levels, genetic health and antioxidant potential (ORAC, TRAC etc), as well as the measurement of stool content and stool pH. At baseline and after 18 weeks salmon consumption No
Other Markers of genetic health The buffy coat from spun whole blood samples will be collected to measure patterns of DNA methylation contributing to epigenetic inheritance. At baseline and after 18 weeks salmon consumption No
Primary Change in the omega-3 index The Omega-3 index will be measured by GC-MS. An optimal target level of the Omega-3 Index is 8%, and an undesirable level is less than 4%, with 4-8% being an intermediate-risk zone. At baseline and after 18 weeks salmon consumption No
Secondary Change in cardiovascular risk markers This study will include the measurement of standard risk markers of cardiovascular disease at the start, middle and end of the intervention period, including lipoprotein metabolism (total cholesterol, LDL cholesterol, HDL cholesterol) and metabolic markers (glucose, insulin, triglycerides and non-esterified fatty acids to calculate HOMA-IR and revised QUICKI). We will also measure 24-hrs ambulatory blood pressure. At baseline, after 9 weeks and after 18 weeks salmon consumption No
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment